31.96
+1.66(+5.48%)
Currency In USD
| Previous Close | 30.3 |
| Open | 30.89 |
| Day High | 32.01 |
| Day Low | 30.34 |
| 52-Week High | 38.93 |
| 52-Week Low | 15.71 |
| Volume | 476,617 |
| Average Volume | 250,347 |
| Market Cap | 899.55M |
| PE | 48.42 |
| EPS | 0.66 |
| Moving Average 50 Days | 26.39 |
| Moving Average 200 Days | 26.6 |
| Change | 1.66 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $1,972.84 as of June 09, 2025 at a share price of $31.96. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 6 months ago, it would be worth $965.56 as of June 09, 2025 at a share price of $31.96.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
May 27, 2025 12:00 PM GMT
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewswire Inc.
May 09, 2025 1:03 PM GMT
Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net salesSAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ)
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
GlobeNewswire Inc.
May 07, 2025 8:05 PM GMT
New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balanc